We studied the interaction of azole antimycotics with intravenous (IV) and oral midazolam using a cross-over design in 12 volunteers, who ingested placebo, itraconazole, or fluconazole for 6 days. A 7.5-mg dose of midazolam was ingested on the first day, 0.05 mg/kg was administered IV on the fourth day, and 7.5 mg orally on the sixth day. Itraconazole reduced the clearance of IV midazolam by 69% and fluconazole reduced the clearance of IV midazolam by 51% (P < 0.001). A single dose of itraconazole and fluconazole increased the area under the oral midazolam concentration-time curve [AUC(O-co)] 3.5-fold (P < 0.001) and the peak concentration two-fold (P < 0.05) compared to placebo. On the sixth day the AUC(O-co) of oral midazolam was almost seven times greater with itraconazole (P < 0.001) and 3.6 times greater with fluconazole (P < 0.001) than without the antimycotics. The psychomotor effects of midazolam were also profoundly increased (P < 0.001). The psychomotor tests demonstrated only a weak interaction between the antimycotics and IV midazolam. When bolus doses of midazolam are given for shorttime sedation, the effect of midazolam is not increased to a clinically significant degree by itraconazole and fluconazole, and it can be used in normal doses. However, the use of large doses of IV midazolam increases the risk of clinically significant interactions also after IV midazolam. Use of oral midazolam with itraconazole and fluconazole should be avoided.
3.6 times greater with fluconazole (P < 0.001) than without the antimycotics. The psychomotor effects of midazolam were also profoundly increased (P < 0.001). The psychomotor tests demonstrated only a weak interaction between the antimycotics and IV midazolam. When bolus doses of midazolam are given for shorttime sedation, the effect of midazolam is not increased to a clinically significant degree by itraconazole and fluconazole, and it can be used in normal doses. However, the use of large doses of IV midazolam increases the risk of clinically significant interactions also after IV midazolam. Use of oral midazolam with itraconazole and fluconazole should be avoided. (Anesth Analg 1996; 82:511-6) 0 xidation reactions are dominant in the metabolism of drugs and the cytochrome P-450 enzymes have been recognized as chief contributors (1). Cytochrome P-450 3A enzymes can metabolize many drugs, including drugs of interest to anesthesiologists [e.g., midazolam, alfentanil, and lidocaine (2-411. In vitro cytochrome P-450 3A enzymes are inhibited by many drugs. For example, calcium antagonists diltiazem and verapamil, antimicrobial drugs erythromycm and troleandomycin, and antimycotics ketoconazole, itraconazole and fluconazole inhibit the cytochrome P-450 3A mediated biotransformation of midazolam (5, 6) . We have shown recently that ketoconazole and itraconazole increase the area under the plasma concentration versus time curve of oral midazolam by lOOO%-1500% (7), but the effect of fluconazole on oral midazolam has not been studied earlier. Because intravenous (IV) midazolam is used worldwide for sedation during minor operations and intensive care, we found it important to study the possible interaction of itraconazole and fluconazole with IV midazolam. Furthermore, we were interested in the speed of onset of the possible antimycotic-induced enzyme inhibition.
Methods
We obtained informed, written consent and institutional approval to study seven male and five female healthy volunteers, aged 19-25 yr and weighing 57-95 kg. None of them were on continuous medication, except for the five female subjects using contraceptive steroids. A randomized, double-blind, cross-over study design, in three phases, was used at intervals of 4 wk. The subjects were given orally, once daily at 1.00 PM, either placebo or itraconazole 200 mg for 6 days or fluconazole 400 mg on the first day and then 200 mg daily for 5 days. The doses are typical clinical doses used for the treatment of systemic mycoses.
The first dose of 7.5 mg of oral midazolam was ingested with 150 mL water on the first day of pretreatment, 2 h after the first dose of placebo, itraconazole or fluconazole. Midazolam 0.05 mg/kg, was administered IV over 2 min on the fourth day of pretreatment. The third dose, 7.5 mg of midazolam Anesth Analg 1996; 82:5114 511 orally, was ingested on the sixth day. Midazolam was always administered 2 h after placebo, itraconazole, or fluconazole doses. A schematic chart of the study design is given in Table 1 . The volunteers fasted for 3 h before administration of midazolam and had a standard meal 4 h afterward. Ingestion of alcohol, coffee, tea, and cola was not allowed during the test days, nor was smoking permitted. Timed blood samples were drawn into EDTA tubes immediately before administration of midazolam and 0.5,1,1.5,2,3,4,5,6, 7, and 17 h after administration. After IV midazolam, an additional blood sample was drawn 15 min after its administration. Plasma itraconazole and fluconazole concentrations were measured from the samples taken 30 min after the administration of midazolam during each phase. Plasma was separated within 30 min and stored at -40°C until midazolam concentrations were analyzed with gas chromatography (9). The sensitivity of the method was 0.1 ng/mL and the coefficient of variation (day to day) was 3.3% at 5.1 ng/mL (n = 6). Itraconazole and fluconazole concentrations were determined by highperformance liquid chromatography (10,ll). The sensitivity of the method for itraconazole was 4 ng/mL and the coefficient of variation was 4.1% at 422 ng/mL (n = 7). The sensitivity of the method for fluconazole was 0.1 pg/mL and the coefficient of variation was 3.6% at 4.09 pg/mL (n = 11).
The pharmacokinetics of midazolam were characterized by areas under the drug plasma concentrationtime curves [AUCfO-a)], peak concentrations (C,,,), concentration peak times (T,,,), and elimination halflives (ti,z). For each subject the terminal log-linear phase of the plasma concentration-time curve was identified visually. The elimination rate constant (k,,) was determined by regression analysis of the loglinear part of the curve. The elimination half-life was calculated from t,,, = In 2/k,,. The areas under the midazolam concentration-time curves were calculated using the linear trapezoidal rule while successive concentration values were increasing, and the logarithmic trapezoidal rule when successive concentration values were decreasing after the peak concentration value. AUC(O-m) was extrapolated to infinity by using the respective k,, value. After IV administration of midazolam, values for plasma clearance (CL) and steadystate volume of distribution (Vss) of midazolam were also calculated using noncompartmental methods based on statistical moment theory. Oral bioavailabilities (F) were calculated during the placebo phase and on the sixth day of pretreatment during itraconazole and fluconazole phases from F = CL * AUC(Ow)oradDOSeoral~ assuming that the CL values measured after IV administration of midazolam remained unchanged between the fourth and the sixth day of pretreatment (12).
The effects of midazolam on psychomotor performance were assessed at the time of blood sampling using the critical flicker-fusion test (CFF), digit symbol substitution test (DSS), the Maddox wing test (MW), and by assessing subjective drowsiness (alert-drowsy) on a lOO-mm-long horizontal visual analog scale (VAS) (7). Subjective drowsiness was assessed by the subjects themselves. For each pharmacodynamic variable the areas under the response-time curves were determined by the trapezoidal rule for O-17 h (CFFAuc, DSSAUc, MWAUc, VAS,&.
The maximum effects over O-17 h (CFFMIN, DSSMVIIN, MWMAx, VASMAx) were also registered (13).
All data were expressed as mean values + SD except in illustrations where mean values + SEM were given. Analysis of variance with repeated measures was used; II posteriori testing was done with Tukey's test. Differences were regarded statistically significant if P < 0.05. Data were analyzed with the statistical program Systat for Windows, version 5.0 (Systat, Evanston, IL).
Results
Itraconazole administration reduced the mean plasma clearance of midazolam by 69% (P < 0.001) and fluconazole by 51% (P < 0.001). The Vs, was unchanged by the antimycotics but both itraconazole and fluconazole prolonged the t,,, (P < 0.001) of midazolam ( Figure 1 ; Table 2 ). The psychomotor tests demonstrated only a relatively weak interaction between the antimycotics and midazolam (Figure 2 and fluconazole phases. DSS,,, differed both between the placebo and fluconazole (P < 0.001) and between the fluconazole and itraconazole (P < 0.05) phases. Other pharmacodynamic differences were not observed.
On the first day of pretreatment, itraconazole and fluconazole increased the mean AUC(0 --oo) of midazolam approximately 3.5-fold (P < O.OOl), and the C,,, 1.8-fold and 2.5-fold, respectively (P < 0.05). Both itraconazole (P < 0.001) and fluconazole (P < 0.05) also increased the t,,, of midazolam ( Figure 1 ; Table  3 ). The effect of itraconazole on the pharmacokinetics of oral midazolam was greater on the sixth day than on the first day; the AUC(O-m), C,,,, and t,,, were almost doubled (P < 0.001). The effect of fluconazole and placebo on the pharmacokinetic variables of midazolam were similar on Days 1 and 6. The high concentrations of midazolam during treatment with antimycotics were associated with increased effects (P < 0.001) in all pharmacodynamic variables (Figure 2 ). The mean plasma itraconazole concentrations during itraconazole phase 30 min after midazolam was given were 80 & 64,352 t 158, and 338 * 187 ng/mL on Days 1, 4, and 6, respectively.
The corresponding fluconazole concentrations were 6.6 t 2.2, 9.0 ? 2.1, and 9.2 + 1.8 pg/mL, respectively. were increased 6.6-fold by itraconazole and 3.6-fold by fluconazole, respectively.
The changes of the pharmacokinetics of oral midazolam resulted from an increase in oral bioavailability and a decrease in plasma CL of midazolam.
When midazolam was given orally, its higher plasma concentrations after previous itraconazole and fluconazole administration were also reflected in all pharmacodynamic measurements. During the placebo phase midazolam caused a short-lasting hypnotic effect only. In contrast to this, administration of midazolam along with itraconazole or fluconazole resulted in undesirably deep and long-lasting hypnotic effects. On the sixth day of pretreatment, the volunteers could hardly be wakened during the first hour after midazolam administration and the scores on the DSS, for example, were still significantly different between the placebo and itraconazole and fluconazole phases up to six hours after administration of midazolam. Thus, patients ingesting even a dose of 7.5 mg of midazolam, e.g., for premeditation during itraconazole and fluconazole treatment, are not likely to be capable of tasks that require skills, such as driving a car, six hours after midazolam administration.
The effect of itraconazole on midazolam was greater on the sixth day than on the first day of pretreatment, Top panels, Results after the oral dose of midazolam, given on the first day. Middle panels, Results after the intravenous dose of midazolam, given on the fourth day. Bottom panels, Results after the second oral dose of midazolam, given on the sixth day. Open circles = psychomotor effects of midazolam after placebo; closed circles = psychomotor effects of midazolam after itraconazole; closed triangles = psychomotor effects of midazolam after fluconazole.
but that of fluconazole was similar. This is undermanufacturer, the initial dose of fluconazole was twice standable because the concentration of itraconazole on the maintenance dose. Nevertheless, both itraconazole the sixth day was approximately four times higher and fluconazole already had a significant interaction than on the first day. On the other hand, the concenwith oral midazolam two hours after their first doses. tration of fluconazole on the sixth day was about
The speed of onset of the antimycotic-induced liver 1.4-fold of that on the first day. This occurrence was enzyme inhibition is in good agreement with studies probably due to the fact that, as recommended by the in vitro. 
Control ( When midazolam was given IV, its pharmacokinetits were not affected to the same extent as after oral administration. However, during itraconazole phase the concentration of midazolam was still, 17 hours after its IV administration, higher than during placebo seven hours after its administration. The pharmacodynamic changes paralleled the changes in pharmacokinetics, and consequently, only minor changes in pharmacodynamics were observed. Because the antimycotics change the pharmacokinetics of oral midazolam both by reducing the first-pass metabolism and by reducing elimination, antimycotics affect the oral pharmacokinetics of midazolam more than that of IV midazolam. The present results agree well with previous reports on the interactions of itraconazole and fluconazole with drugs metabolized by the cytochrome P-450 3A (14,15). Compared to our previous study on the interaction between erythromycin and midazolam, fluconazole decreases midazolam CL to the same extent as erythromycin, but itraconazole reduces midazolam CL more effectively than erythromycin (16).
Midazolam is metabolized by cytochrome P-450 3A enzymes (3) and studies in vitro have suggested that an interaction between midazolam and itraconazole and fluconazole is possible (5,6). When azole antimycotics were studied for their effect on the metabolism of cyclosporin by human liver microsomes, IC,, values demonstrated that ketoconazole is the most potent inhibitor of the metabolism of this cytochrome P-450 3A substrate, followed by itraconazole and fluconazole (8). However, although the inhibition of midazolam metabolism by fluconazole in vitro is much less than that by itraconazole at equimolar concentrations, the plasma concentration of fluconazole was, on the sixth day in the present study, approximately 30 times higher than that of itraconazole. In vitro experiments have only a limited value in predicting the magnitude of drug interactions in humans because the concentrations of the inhibitor and the substrate at the site of the interaction often are unknown.
The interaction of orally administered midazolam with itraconazole and fluconazole is clearly of major clinical significance. Fluconazole, and especially itraconazole, may dangerously increase the depth of sleep and prolong the hypnotic effect of oral midazolam. The interaction of IV midazolam with itraconazole and fluconazole is of less clinical significance than that between the antimycotics and oral midazolam. Both itraconazole and fluconazole decrease the CL of midazolam, but the V, values remain unchanged. This suggests that when bolus doses of IV midazolam are given, e.g., for sedation during minor surgical procedures, the effect of midazolam is not increased to a 
